Amprologix wins DHSC backing for new antibiotic

RNS Number : 8922O

Frontier IP Group plc

04 February 2019

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

Portfolio news - Amprologix wins £1.2 million UK Department of Health and Social Care SBRI funding to accelerate new antibiotic development to combat resistant superbugs

Frontier IP, a specialist in commercialising university intellectual property, today announces portfolio company Amprologix (the "Company") has won a contract worth £1.2 million funded by the UK Department for Health and Social Care to accelerate development and scale up its lead antibiotic candidate to tackle antimicrobial resistant MRSA and related superbugs.

The contract from the Small Business Research Initiative ("SBRI"), administered by Innovate UK, will be used to make the Company's epidermicin NI01 antibiotic ready for phase 1 human clinical trials during early 2021.

Epidermicin NI01 is the lead candidate in a new family of epidermicin-based antibiotics being developed by Amprologix, a spin out from the University of Plymouth.  Amprologix was established last year to commercialise the work of Mathew Upton, Professor of Medical Microbiology at the University's Institute of Translational and Stratified Medicine.  

The Company has already secured industry involvement. Ingenza, a leader in industrial biotechnology and synthetic biology, is also a shareholder, and Frontier IP holds a 10 per cent stake in return for providing a range of commercialisation services.  Amprologix's first product is expected to be a nasal cream containing NI01 to prevent MRSA infections.

For the project, Professor Upton will optimise the formulation of epidermicin and conduct a pre-clinical toxicology evaluation.  Amprologix will license optimised microbial based production technology from Ingenza's biologics manufacturing platform to produce the new antibiotics at scale.

Professor Upton is also working separately with Ingenza, IBM and the National Physical Laboratory, using Artificial Intelligence to create a portfolio of novel, adaptable antibiotic candidates for future exploitation.

Epidermicin is derived from bacteria found on human skin.  Work conducted to date shows a single dose was as effective as six doses of the current gold standard treatment in a relevant model of MRSA infection.  Antimicrobial-resistant bacteria kill more than 25,000 people a year in Europe, while MRSA was named in 2017 as a "high priority" target for antibiotic research by the World Health Organisation.

Professor Upton initially developed the patented technology while at The University of Manchester, which owns an equity share of the business through UMI3 Ltd, its IP commercialisation arm.

Professor Mathew Upton, chief scientific officer at Amprologix, said: "I feel very strongly that epidermicin has excellent potential for use in nasal decolonisation to prevent skin and wound infections, like those caused by MRSA.  Development of NI01 could have immense benefits for patients, so I'm genuinely excited about this work and generating the data needed to enter phase 1 trials."

Dr Gordon Barker, chief executive officer of Amprologix, said "Despite the urgent need for new antibiotics and new approaches to treatment, it remains extremely difficult to fund new drug discovery ventures in this space.  The government-backed SBRI programme is a world-leading scheme to address this market failure and we're really grateful for their support, which will accelerate the development of next generation life-saving medicines like NI01."

Dr Ian Fotheringham, managing director of Ingenza, said: "We are developing advanced biologics manufacturing technologies to address exactly this kind of critical unmet therapeutic need.  Our platform will underpin the future success of this exciting new family of potent and selective antimicrobials."

Neil Crabb, chief executive officer of Frontier IP, said: "We are delighted the SBRI is backing this programme, which validates our approach to IP commercialisation. Through Amprologix and Professor Upton's ground-breaking science, there is huge potential to prove the efficacy of epidermicin and identify further new antibiotics that can be manufactured at scale."

ENQUIRIES

Frontier IP Group Plc	T: 0131 240 1251
Neil Crabb, Chief Executive Andrew Johnson, Communications & Investor Relations Company website: www.frontierip.co.uk	M: 07464 546 025
Allenby Capital Limited (Nominated Adviser and Broker)	T: 0203 328 5656
Nick Athanas / Nicholas Chambers (Corporate Finance) Amrit Nahal (Equity Sales)

NOTES TO EDITORS

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

ABOUT THE UNIVERSITY OF PLYMOUTH

The University of Plymouth is renowned for high quality, internationally-leading education, research and innovation.

With a mission to Advance Knowledge and Transform Lives, Plymouth is a *top 50 research university with clusters of world class research across a wide range of disciplines including marine science and engineering, medicine, robotics and psychology. A twice winner of the Queen's Anniversary Prize for Higher Education, the University of Plymouth continues to grow in stature and reputation.

It has a strong track record for teaching and learning excellence and has one of the highest numbers of National Teaching Fellows of any UK university. With 21,000 students, and a further 17,000 studying for a Plymouth degree at partner institutions in the UK and around the world, and over 100,000 alumni pursuing their chosen careers globally, it has a growing global presence.

http://www.plymouth.ac.uk

* Research Fortnight Research Power League Table 2014.

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain.   Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

END

 

 

NRALLFEEFEILIIA